Arcus Biosciences (RCUS) Tops Q4 EPS by 20c

Arcus Biosciences (NYSE: RCUS) reported Q4 EPS of ($1.03), $0.20 better than the analyst estimate of ($1.23). Revenue for the quarter came in at $36 million versus the consensus estimate of $29.33 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Bending Spoons valuation up to $19 Billion in U.S. IPO - Reuters
• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ